KR20080104350A - 치매 및 다른 신경 장애의 진단을 위한 방법 - Google Patents
치매 및 다른 신경 장애의 진단을 위한 방법Info
- Publication number
- KR20080104350A KR20080104350A KR1020087023687A KR20087023687A KR20080104350A KR 20080104350 A KR20080104350 A KR 20080104350A KR 1020087023687 A KR1020087023687 A KR 1020087023687A KR 20087023687 A KR20087023687 A KR 20087023687A KR 20080104350 A KR20080104350 A KR 20080104350A
- Authority
- KR
- South Korea
- Prior art keywords
- metabolite
- dementia
- metabolites
- sample
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 278
- 238000000034 method Methods 0.000 title claims abstract description 182
- 238000003745 diagnosis Methods 0.000 title claims description 25
- 208000012902 Nervous system disease Diseases 0.000 title description 11
- 208000025966 Neurological disease Diseases 0.000 title description 9
- 239000002207 metabolite Substances 0.000 claims abstract description 472
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 238000002372 labelling Methods 0.000 claims abstract description 35
- 239000000523 sample Substances 0.000 claims description 128
- 208000010877 cognitive disease Diseases 0.000 claims description 100
- 210000002966 serum Anatomy 0.000 claims description 98
- 208000028698 Cognitive impairment Diseases 0.000 claims description 91
- 238000001228 spectrum Methods 0.000 claims description 76
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 54
- 150000002500 ions Chemical class 0.000 claims description 53
- 238000004458 analytical method Methods 0.000 claims description 51
- 239000013074 reference sample Substances 0.000 claims description 49
- 229910052698 phosphorus Inorganic materials 0.000 claims description 46
- 230000002829 reductive effect Effects 0.000 claims description 41
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 37
- 238000004811 liquid chromatography Methods 0.000 claims description 18
- 230000009467 reduction Effects 0.000 claims description 14
- 230000000052 comparative effect Effects 0.000 claims description 13
- 230000007792 alzheimer disease pathology Effects 0.000 claims description 12
- 238000000534 ion trap mass spectrometry Methods 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 11
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 239000013610 patient sample Substances 0.000 claims description 8
- 239000006227 byproduct Substances 0.000 claims description 7
- 235000004626 essential fatty acids Nutrition 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 5
- 238000004252 FT/ICR mass spectrometry Methods 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 3
- 230000001925 catabolic effect Effects 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 description 193
- 239000000090 biomarker Substances 0.000 description 74
- 239000012634 fragment Substances 0.000 description 43
- 238000012360 testing method Methods 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000007935 neutral effect Effects 0.000 description 20
- -1 ethanolamine phospholipids Chemical class 0.000 description 18
- 238000009826 distribution Methods 0.000 description 16
- 230000036541 health Effects 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 15
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 14
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 230000008449 language Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 10
- 238000003748 differential diagnosis Methods 0.000 description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 9
- 210000004884 grey matter Anatomy 0.000 description 9
- 210000004885 white matter Anatomy 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
- 230000006978 adaptation Effects 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 208000027061 mild cognitive impairment Diseases 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 7
- 208000035850 clinical syndrome Diseases 0.000 description 7
- 238000001360 collision-induced dissociation Methods 0.000 description 7
- 101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 201000004810 Vascular dementia Diseases 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000013498 tau Proteins Human genes 0.000 description 5
- 108010026424 tau Proteins Proteins 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000010855 neuropsychological testing Methods 0.000 description 4
- 238000000899 pressurised-fluid extraction Methods 0.000 description 4
- 238000003325 tomography Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000017004 dementia pugilistica Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000002038 ethyl acetate fraction Substances 0.000 description 3
- 238000004401 flow injection analysis Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000005802 health problem Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002981 neuropathic effect Effects 0.000 description 3
- 230000003557 neuropsychological effect Effects 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical group NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005257 alkyl acyl group Chemical group 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 238000001977 collision-induced dissociation tandem mass spectrometry Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000011141 high resolution liquid chromatography Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005040 ion trap Methods 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000007884 metabolite profiling Methods 0.000 description 2
- 238000000874 microwave-assisted extraction Methods 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000006403 short-term memory Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Chemical group 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KXEMQEGRZWUKJS-UHFFFAOYSA-N Raufloridine Natural products COC1=CC=C2C(CCN3CC4C(C)OC=C(C4CC33)C(=O)OC)=C3NC2=C1 KXEMQEGRZWUKJS-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000036403 neuro physiology Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007121 neuropathological change Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 210000000701 subdural space Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N37/00—Details not covered by any other group of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/16—Phosphorus containing
- Y10T436/163333—Organic [e.g., chemical warfare agents, insecticides, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Primary Health Care (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77729006P | 2006-02-28 | 2006-02-28 | |
| US60/777,290 | 2006-02-28 | ||
| US80477906P | 2006-06-14 | 2006-06-14 | |
| US60/804,779 | 2006-06-14 | ||
| US88888307P | 2007-02-08 | 2007-02-08 | |
| US60/888,883 | 2007-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080104350A true KR20080104350A (ko) | 2008-12-02 |
Family
ID=38458611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087023687A Withdrawn KR20080104350A (ko) | 2006-02-28 | 2007-02-28 | 치매 및 다른 신경 장애의 진단을 위한 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8304246B2 (https=) |
| EP (3) | EP2851369A3 (https=) |
| JP (3) | JP5496513B2 (https=) |
| KR (1) | KR20080104350A (https=) |
| AT (1) | ATE535535T1 (https=) |
| AU (1) | AU2007219666A1 (https=) |
| CA (2) | CA2689848A1 (https=) |
| HK (1) | HK1208467A1 (https=) |
| IL (1) | IL193426A0 (https=) |
| NZ (1) | NZ570413A (https=) |
| WO (1) | WO2007098585A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2117527B1 (en) | 2007-02-08 | 2020-06-17 | Med-Life Discoveries LP | Compounds for use in the treatment of senile dementia of the alzheimer's type |
| CA2680748C (en) * | 2007-04-13 | 2012-08-28 | Phenomenome Discoveries Inc. | Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging |
| JP5306345B2 (ja) * | 2007-07-26 | 2013-10-02 | フェノメノーム ディスカバリーズ インク | 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法 |
| MX340916B (es) | 2008-01-18 | 2016-07-29 | President And Fellows Of Harvard College * | Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales. |
| US20140365895A1 (en) | 2008-05-13 | 2014-12-11 | Apple Inc. | Device and method for generating user interfaces from a template |
| US9121844B1 (en) * | 2008-09-09 | 2015-09-01 | Sociedad Europea de Analisis Diferencial de Movilidad | Method to analyze and classify persons and organisms based on odor patterns from released vapors |
| TWI475989B (zh) | 2008-12-22 | 2015-03-11 | Phenomenome Discoveries Inc | 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法 |
| EP3124980A1 (en) | 2009-10-01 | 2017-02-01 | Phenomenome Discoveries Inc. | Mass spectrophotometric method to diagnose pancreatic cancer |
| US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
| EP2596132A4 (en) | 2010-07-23 | 2013-12-18 | Harvard College | METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS |
| AU2011280997A1 (en) | 2010-07-23 | 2013-02-28 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| TW201209171A (en) | 2010-07-23 | 2012-03-01 | Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| WO2012090625A1 (ja) * | 2010-12-28 | 2012-07-05 | 医療法人社団ブックス | 認知症を血液サンプルで判定するための検査方法 |
| AU2012321071B2 (en) * | 2011-11-17 | 2015-02-26 | Med-Life Discoveries Lp | Methods for the synthesis of 13C labeled plasmalogen |
| WO2013119651A1 (en) * | 2012-02-08 | 2013-08-15 | Nestec Sa | Methods for diagnosing cognitive impairment |
| US20150031572A1 (en) * | 2012-02-15 | 2015-01-29 | Basf Se | Means and methods for assessing neuronal toxicity |
| CN104246781B (zh) * | 2012-03-29 | 2019-06-14 | 皇家飞利浦有限公司 | 用于改进神经科医师的关于阿尔茨海默氏病的工作流程的系统与方法 |
| MX2014015434A (es) | 2012-06-15 | 2015-07-14 | Harry Stylli | Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion. |
| JP2015522260A (ja) | 2012-06-15 | 2015-08-06 | ハリー スティリ， | 疾患または状態を検出する方法 |
| NZ771629A (en) | 2013-03-09 | 2022-12-23 | Harry Stylli | Methods of detecting cancer |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| DE202014004560U1 (de) * | 2013-06-08 | 2014-09-12 | Apple Inc. | Vorrichtung und grafische Benutzerschnittstelle zum Synchronisieren zweier oder mehrerer Anzeigen |
| CA2926592A1 (en) * | 2013-11-14 | 2015-05-21 | Nestec S.A. | Lipid biomarkers of healthy ageing |
| WO2015138879A1 (en) * | 2014-03-13 | 2015-09-17 | Massachusetts Institute Of Technology | Compositions containing pufa, uridine and choline and methods of use thereof |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| US10006925B2 (en) | 2016-05-30 | 2018-06-26 | Universal Diagnostics, S. L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
| GB201611596D0 (en) * | 2016-07-04 | 2016-08-17 | British American Tobacco Investments Ltd | Apparatus and method for classifying a tobacco sample into one of a predefined set of taste categories |
| US20200241011A1 (en) * | 2017-02-24 | 2020-07-30 | Mattias ARNOLD | Compositions and methods related to sex- specific metabolic drivers in alzheimers disease |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| US20190385711A1 (en) | 2018-06-19 | 2019-12-19 | Ellipsis Health, Inc. | Systems and methods for mental health assessment |
| JP7608171B2 (ja) | 2018-06-19 | 2025-01-06 | エリプシス・ヘルス・インコーポレイテッド | 精神的健康評価のためのシステム及び方法 |
| JP7389421B2 (ja) * | 2018-07-13 | 2023-11-30 | Ｐｓｔ株式会社 | 精神・神経系疾患を推定する装置 |
| US11452839B2 (en) | 2018-09-14 | 2022-09-27 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| WO2022263927A2 (en) * | 2021-06-17 | 2022-12-22 | Phoska Biopharma Pte. Ltd. | Plasmalogen derivatives and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009371A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| US5731354A (en) | 1996-05-06 | 1998-03-24 | Clarion Pharmaceuticals Inc. | Treatment for the inhibition of neuro-degenerative disease states |
| US6177476B1 (en) | 1998-08-27 | 2001-01-23 | Clarion Pharmaceuticals Inc. | Nutritional supplements for replenishing plasmalogens |
| CA2298181C (en) | 2000-02-02 | 2006-09-19 | Dayan Burke Goodnough | Non-targeted complex sample analysis |
| US20020009740A1 (en) | 2000-04-14 | 2002-01-24 | Rima Kaddurah-Daouk | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| AU2001286059A1 (en) * | 2000-09-08 | 2002-03-22 | Oxford Glycosciences (Uk) Ltd. | Automated identification of peptides |
| WO2002082075A2 (de) | 2001-04-06 | 2002-10-17 | Biovision Ag | Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien |
| CA2446666A1 (en) * | 2001-05-09 | 2002-11-14 | Biovision Ag | Method for detecting progredient chronic dementia, and associated peptides and detection reagents |
| CA2745998C (en) * | 2002-08-23 | 2013-11-26 | Bayer Schering Pharma Aktiengesellschaft | Biomarkers for diagnosing alzheimer's disease |
| US7794948B2 (en) | 2003-11-07 | 2010-09-14 | Vermilllion, Inc. | Biomarkers for alzheimer's disease |
| WO2005085838A2 (en) * | 2004-03-02 | 2005-09-15 | Vanderbilt University | Computational analysis of mass spectroscopic lipid data |
| WO2005116659A2 (en) * | 2004-05-18 | 2005-12-08 | Neurodx, Llc | Compositions and methods relating to alzheimer’s disease |
| JP4176749B2 (ja) * | 2005-07-29 | 2008-11-05 | 学校法人帝京大学 | 疾病検査法 |
| US8026099B2 (en) * | 2007-07-26 | 2011-09-27 | Washington University | Lipid profile as a biomarker for early detection of neurological disorders |
-
2007
- 2007-02-28 CA CA2689848A patent/CA2689848A1/en not_active Abandoned
- 2007-02-28 EP EP14187832.2A patent/EP2851369A3/en not_active Withdrawn
- 2007-02-28 WO PCT/CA2007/000313 patent/WO2007098585A1/en not_active Ceased
- 2007-02-28 US US12/280,920 patent/US8304246B2/en active Active
- 2007-02-28 JP JP2008556622A patent/JP5496513B2/ja active Active
- 2007-02-28 EP EP10195818A patent/EP2322531A3/en not_active Ceased
- 2007-02-28 CA CA2640748A patent/CA2640748C/en active Active
- 2007-02-28 KR KR1020087023687A patent/KR20080104350A/ko not_active Withdrawn
- 2007-02-28 EP EP07710657A patent/EP1922325B1/en active Active
- 2007-02-28 AT AT07710657T patent/ATE535535T1/de active
- 2007-02-28 AU AU2007219666A patent/AU2007219666A1/en not_active Abandoned
- 2007-02-28 NZ NZ570413A patent/NZ570413A/en unknown
-
2008
- 2008-08-08 HK HK15109254.5A patent/HK1208467A1/en unknown
- 2008-08-13 IL IL193426A patent/IL193426A0/en unknown
-
2012
- 2012-07-31 JP JP2012169181A patent/JP2012255793A/ja active Pending
- 2012-09-25 US US13/626,703 patent/US20130110408A1/en not_active Abandoned
-
2014
- 2014-06-26 JP JP2014131876A patent/JP2014197018A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2322531A2 (en) | 2011-05-18 |
| JP2009528517A (ja) | 2009-08-06 |
| JP2012255793A (ja) | 2012-12-27 |
| EP1922325A4 (en) | 2009-05-27 |
| JP5496513B2 (ja) | 2014-05-21 |
| EP1922325A1 (en) | 2008-05-21 |
| ATE535535T1 (de) | 2011-12-15 |
| WO2007098585A1 (en) | 2007-09-07 |
| AU2007219666A1 (en) | 2007-09-07 |
| JP2014197018A (ja) | 2014-10-16 |
| IL193426A0 (en) | 2009-05-04 |
| EP2322531A3 (en) | 2011-09-07 |
| EP2851369A3 (en) | 2015-06-17 |
| NZ570413A (en) | 2011-07-29 |
| CA2640748A1 (en) | 2007-09-07 |
| HK1208467A1 (en) | 2016-03-04 |
| US20130110408A1 (en) | 2013-05-02 |
| CA2689848A1 (en) | 2007-09-07 |
| CA2640748C (en) | 2010-04-20 |
| EP2851369A2 (en) | 2015-03-25 |
| EP1922325B1 (en) | 2011-11-30 |
| HK1113160A1 (en) | 2008-09-26 |
| US8304246B2 (en) | 2012-11-06 |
| US20100003761A1 (en) | 2010-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080104350A (ko) | 치매 및 다른 신경 장애의 진단을 위한 방법 | |
| US8026099B2 (en) | Lipid profile as a biomarker for early detection of neurological disorders | |
| JP5977795B2 (ja) | 多発性硬化症を診断するための生物マーカー、及びその方法 | |
| JP5306345B2 (ja) | 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法 | |
| Iriondo et al. | Isopropanol extraction for cerebrospinal fluid lipidomic profiling analysis | |
| JP2010523986A (ja) | プラスマロゲン欠乏症が媒介する加齢に伴う疾患の診断及びリスク評価のための方法 | |
| WO2018191866A1 (zh) | 2型糖尿病标志物及其用途 | |
| CN101395163A (zh) | 诊断痴呆和其它神经病症的方法 | |
| AU2016206360B2 (en) | Methods for the diagnosis of dementia and other neurological disorders | |
| EP4370931B1 (en) | Biomarkers for alzheimer's disease | |
| HK1154013A (en) | Methods for the diagnosis of dementia and other neurological disorders | |
| HK1113160B (en) | Methods for the diagnosis of dementia and other neurological disorders | |
| Huang | Mass Spectrometry-Based Metabolomics: Platform Development and Application to Neurodegenerative Disease | |
| HK1184435A (en) | Biomarkers for diagnosing multiple sclerosis, and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080926 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |